The battle against the rare Kyasanur Forest Disease (KFD), which is known as “Monkey Fever,” pandemic has made history itself. The Union Health Ministry on 7th February, 2026 declared that India has not only evolved a fully indigenous vaccination but also it has been officially put under Phase I human trials.
This landmark accomplishment led by the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) with support from Indian Immunologicals Limited (IIL), is a departure from several decades’ emphasis on a less efficacious formalin-inactivated vaccine. With a nod from the Central Drugs Standard Control Organisation (CDSCO), the new vaccine offers hope of a stronger protection to communities residing in ecologically fragile Western Ghats.
The Modern Solution: Why a New Vaccine?
For more than 60 years now, the people of the Western Ghats—stretching across Karnataka, Tamil Nadu, Kerala, Goa and Maharashtra—have lived in the seasonal shadow cast by KFD. The old vaccine solved a number of problems but was problematic in its own right:
- Decline in Immunity: It became far less effective after just a few months, necessitating booster shots often.
- Production Obstacle: The older vaccine was based on technology using mouse-brain-passaged virus, a hard process to scale.
- Low Efficacy: The older shots offered just 62% protection in studies and often failed to protect forest workers.
The new entry is a two-dose adjuvanted inactivated vaccine. Using a particular viral strain (NIV 164187) and current adjuvants, researchers hope to elicit a more profound immune response that will last longer. The two doses are to be given 28 days apart, a less onerous immunization schedule for rural health workers.
Nipah Virus Alert in West Bengal- Five Infected, Nearly 100 Quarantined
The Scientific Journey: Lab to Human Volunteers
“The path to this announcement has included extensive preclinical testing to ensure any vaccine meets the highest standards of safety and effectiveness. The Health Ministry said that the vaccine had already passed the most important stages of early development.
Completed Preclinical Milestones:
- Animal Challenge Studies: The vaccine showed a strong protective efficacy in animal models by neutralizing the virus after challenge.
- Toxicity Testing: Extensive analysis revealed no toxicity, setting the stage for human trials.
- GLP- Grade Manufacturing: A GLP grade vaccine material of subunit swPV has already been successfully produced in preparation for the clinical trials.
The Phase I Trial Details
The currently ongoing Phase I trial is in healthy volunteers. The primary objective is safety and tolerability of the vaccine in humans.
- Participants: Apparently healthy adults 18–49 years of age, most from areas where hookworm is endemic.
- Surveillance: Broadening the net to include interleukin-6 and interferon-gamma testing and following volunteers for one year (366 days) to measure antibody longevity.
- Timeline: An update from the DSMB is anticipated over the next two months. In the event that its safety is established, the project will seamlessly transition into Phase II in order to evaluate the real efficacy of the vaccine (immunogenicity).
A Smart Partner: Collaboration between Centre, States
This vaccine push was a one-two punch. The project was prioritised after a special request from the Government of Karnataka as the State is witnessing an uptick in cases particularly in districts such as Shivamogga and Uttara Kannada.
By financing it partial through government grants and CSR funding to the tune of around ₹10 crore, the ICMR has managed to make sure that this vaccine is a health issue not just commercial enterprise.
The Role of “One Health”
It’s also part of India’s “One Health” plan that acknowledges the health of humans is connected to that of animals and the environment. Because KFD often begins with a “monkey die-off” in the forest, the vaccine, combined with enhanced forest surveillance and community education, will provide a multilayered defensive strategy.
Health experts scramble to contain outbreak of deadly Nipah virus
What’s Next for Western Ghats?
As the trials advance, the Health Ministry has called on local authorities to maintain strict preventative measures. Until we have a vaccine for widespread use, the emphasis is on:
- Repellents for Ticks: 2.4 Reliable supply of DMP oil to people living in the forest areas.
- Early Diagnosis 1: Increasing the pool of labs able to test for KFD by RT-PCR.
- Surveillance: Following monkey deaths to predict outbreaks among humans.
Its progress to human trials is more than a scientific breakthrough: It’s a hopeful signal for thousands of farmers and forest workers who have long lived with the “ticking health bomb.”
A versatile writer mainly works on trending news, daily updates from politics, business, crime, current affairs and entertainment.
